Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Pharmala Biotech Holdings Inc. (MDMA.CN)

Pharmala Biotech Holdings Inc. (MDMA.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 17,420
  • Shares Outstanding, K 84,976
  • Annual Sales, $ 532 K
  • Annual Income, $ -780 K
  • 60-Month Beta N/A
  • Price/Sales 13.63
  • Price/Cash Flow N/A
  • Price/Book 11.55
Trade MDMA.CN with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.01
  • Most Recent Earnings $0.00 on N/A
  • Latest Earnings Date N/A
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    TSX Biotechnology

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1750 +17.14%
on 04/16/24
0.2400 -14.58%
on 04/08/24
+0.0100 (+5.13%)
since 04/03/24
3-Month
0.1550 +32.26%
on 03/20/24
0.3500 -41.43%
on 02/05/24
-0.0750 (-26.79%)
since 02/02/24
52-Week
0.0850 +141.18%
on 11/29/23
0.4850 -57.73%
on 05/16/23
-0.2150 (-51.19%)
since 05/03/23

Most Recent Stories

More News
Red Light Holland Commences Experimental Research on Psilocybin Truffles to Develop Process for Commercial Manufacturing of Natural-Source Active Pharmaceutical Ingredient

Toronto, Ontario--(Newsfile Corp. - March 8, 2024) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland" or the "Company"), a company engaged in the production, growth and...

MDXXF : 0.1699 (+12.59%)
TRUFF : 0.0439 (+9.48%)
MDMA.CN : 0.2050 (+7.89%)
TRIP.CN : 0.0550 (unch)
FILAMENT HEALTH AND PHARMALA BIOTECH ANNOUNCE RELEASE OF GMP MDMA CAPSULES

/CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company,...

FLHLF : 0.0369 (+7.27%)
MDMA.CN : 0.2050 (+7.89%)
PharmAla appoints Dr. Leah Mayo to Scientific Advisory Board

/CNW/ - PharmAla Biotech (CSE: MDMA) is excited to welcome Dr. Leah Mayo to the company's Scientific Advisory Board. Dr. Mayo recently took up the role of...

MDMA.CN : 0.2050 (+7.89%)
PharmAla Contracts with Clerkenwell to bring safer MDMA analogue to US, UK

/CNW/ - PharmAla Biotech (CSE: MDMA) is pleased to announce that it has retained Clerkenwell Health, a UK-based Contract Research Organization, to assist...

MDMA.CN : 0.2050 (+7.89%)
PharmAla Biotech ready to assist Alberta Government with Clinical MDMA supply

/CNW/ - PharmAla Biotech (CSE: MDMA), currently the only manufacturer of GMP MDMA in Canada, stands ready to assist the Government of Alberta in supplying...

MDMA.CN : 0.2050 (+7.89%)
Stocks in play: Pharmala Biotech Holdings Inc

Have been selected as the MDMA manufacturing partner for the University of Sydney's upcoming Phase 2 ...

MDMA.CN : 0.2050 (+7.89%)
Stocks in play: Pharmala Biotech Holdings Inc

Announces the filing of a key Patent Cooperation Treaty application, containing 6 Novel Chemical Entities. ...

MDMA.CN : 0.2050 (+7.89%)
PharmAla Biotech completes filing of Patent application for 6 MDMA analogs

/CNW/ - PharmAla Biotech (CSE: MDMA) is pleased to announce the filing of a key Patent Cooperation Treaty (PCT) application, containing 6 Novel Chemical...

MDMA.CN : 0.2050 (+7.89%)
PharmAla Biotech First Publicly Traded Company to Produce GMP MDMA

/CNW/ - PharmAla Biotech (CSE: MDMA) (the 'Company') has achieved a historic milestone: it is currently the only publicly-traded company to have produced GMP...

MDMA.CN : 0.2050 (+7.89%)
Stocks in play: Pharmala Biotech Holdings Inc

Announces it has signed on to act as exclusive supplier of both GMP LaNeoâ„¢ MDMA and Engineering MDMA ...

MDMA.CN : 0.2050 (+7.89%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Pharmala Biotech Holdings Inc is focused on manufacturing and sales of MDMA and MDXX Active Pharmaceutical Ingredients (API) for use in clinical research. PharmAla's drug API is manufactured and encapsulated under GMP conditions. The Company generates revenue from the sale of tablets and raw MDMA...

See More

Key Turning Points

3rd Resistance Point 0.2367
2nd Resistance Point 0.2283
1st Resistance Point 0.2167
Last Price 0.2050
1st Support Level 0.1967
2nd Support Level 0.1883
3rd Support Level 0.1767

See More

52-Week High 0.4850
Fibonacci 61.8% 0.3322
Fibonacci 50% 0.2850
Fibonacci 38.2% 0.2378
Last Price 0.2050
52-Week Low 0.0850

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar